Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-134-VI Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0531 0.00467
MDA-MB-134-VI INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9671 -0.00323
MDA-MB-231 Volasertib
0.00031623
PLK
Cell cycle
 1.0754 -0.00092
MDA-MB-157 Volasertib
0.00031623
PLK
Cell cycle
 1.0814 -0.00135
HCC70 Luminespib
0.00031623
HSP90
Misc
 1.1956 -0.00338
BT-20 Luminespib
0.00031623
HSP90
Misc
 1.0678 -0.00788
MDA-MB-231 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9126 0.00521
MDA-MB-134-VI Taxol
0.00031623
Chemo
Chemotherapy
 0.5566 0.10198
MDA-MB-134-VI Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9508 0.00935
SUM149PT Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0357 0.00014
SUM149PT INK-128
0.00031623
mTORC1/2
PI3K/mTOR
 0.9969 -0.00213
MDA-MB-134-VI Luminespib
0.00031623
HSP90
Misc
 1.3361 -0.01039
MDA-MB-134-VI Volasertib
0.00031623
PLK
Cell cycle
 1.4141 0.00230
MCF7 Doxorubicin
0.00031623
Chemo
Chemotherapy
 0.9780 0.00219
T47D Dinaciclib
0.00031623
pan CDK
Cell cycle
 0.9825 0.00122
MDA-MB-134-VI Dinaciclib
0.00031623
pan CDK
Cell cycle
 1.0543 -0.01056
MDA-MB-134-VI Palbociclib
0.00031623
CDK4/6
Cell cycle
 1.1665 -0.00514
T47D Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9443 0.00270
MDA-MB-134-VI Doxorubicin
0.00031623
Chemo
Chemotherapy
 1.1909 0.00067
HCC1806 Luminespib
0.00031623
HSP90
Misc
 0.9805 0.00293
PDX1258 Palbociclib
0.00031623
CDK4/6
Cell cycle
 1.0505 0.00024
MCF7 Taxol
0.00031623
Chemo
Chemotherapy
 0.9160 0.00338
HCC70 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0376 0.01123
MDA-MB-231 Taxol
0.00031623
Chemo
Chemotherapy
 0.9486 0.01025
MDA-MB-231 Trametinib
0.00031623
MEK
MAPK/nRTK
 0.9574 0.01575